For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might
provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …

Since its discovery as a primary component in cytoplasmic aggregates in post-mortem tissue
of patients with Amyotrophic Lateral Sclerosis (ALS), TAR DNA Binding Protein 43 kDa (TDP …

Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured
not only in cerebrospinal fluid but also in serum, which allows for repeated assessments …

Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …